MENJUGATE KIT 10 Microgram Pdr+Solv for Susp for Inj

Country: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

NEISSERIA MENINGITIDIS C, CORYNEBACTERIUM DIPHTHERIAE CRM197 CARRIER PROTEIN

Disponibbli minn:

GSK Vaccines S.r.l.

Kodiċi ATC:

J07AH05

INN (Isem Internazzjonali):

NEISSERIA MENINGITIDIS C, CORYNEBACTERIUM DIPHTHERIAE CRM197 CARRIER PROTEIN

Dożaġġ:

10 Microgram

Għamla farmaċewtika:

Pdr+Solv for Susp for Inj

Tip ta 'preskrizzjoni:

Product subject to prescription which may not be renewed (A)

Żona terapewtika:

Meningococcal vaccines

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2005-04-22

Fuljett ta 'informazzjoni

491650
MENJUGATE
PACKAGE LEAFLET: INFORMATION FOR THE USER
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR
CHILD START USING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU OR YOUR CHILD.
- Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This vaccine has been prescribed for you or your child only.
Do not pass it on to others.
- If you or your child get any side effects, talk to your doctor
or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1. What Menjugate is and what it is used for
2. What you need to know before you or your child use
Menjugate
3. How to use Menjugate
4. Possible side effects
5. How to store Menjugate
6. Content of the pack and other information
1. WHAT MENJUGATE IS AND WHAT IT IS USED FOR
Menjugate is a vaccine that is used to prevent disease caused
by a bacterium named _Neisseria meningitidis_ group C (also
referred to as meningococcal group C bacteria). The vaccine
works by causing your body to make its own protection
(antibodies) against these meningococcal group C bacteria.
_Neisseria meningitidis_ group C bacteria can cause serious
and sometimes life-threatening infections such as
meningitis and septicaemia (blood poisoning).
This vaccine is used for active immunisation of children
from 2 months of age, adolescents and adults and
it can only protect against meningococcal group C
bacteria. It cannot protect against other groups (strains)
of_ _meningococcal bacteria or against other causes of
meningitis and septicaemia (blood poisoning). If at any
time you or your child experiences neck pain, neck stiffness
or a dislike of light (photophobia), drowsiness or confusion,
red or purple bruise-like spots that do not fade under
pressure you must contact your doctor or local Accident
and Emergency Department immediately.
THIS VACCINE CANNOT CAUSE MENINGITIS C
(MENINGOCOCCAL GROUP C DISEASE).
• have an INFECTIOUS ILLNESS OR HIGH FEVER. In this

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
MENJUGATE KIT 10 micrograms powder and solvent for suspension for
injection
Meningococcal group C conjugate vaccine
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (0.5 ml of the reconstituted vaccine) contains:
_Neisseria meningitidis_ group C (strain C11) oligosaccharide
10 micrograms
Conjugated to
_Corynebacterium diphtheriae_ CRM197 protein
1
12.5 to 25.0 micrograms
adsorbed on aluminium hydroxide
0.3 to 0.4 mg Al
3+
1
CRM197 (Cross Reacting Material 197)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder and solvent for suspension for injection.
Powder (vial): white to off-white
Suspension (syringe): white opalescent
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Active immunisation of children from 2 months of age, adolescents and
adults, for the prevention of invasive disease
caused by_ Neisseria meningitidis_ group C.
The use of Menjugate Kit should be determined on the basis of official
recommendations.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Paediatric population_
Primary immunisation
Infants from 2 months of age up to 12 months: two doses, each of 0.5
ml, should be given with an interval of at least 2
months between the doses (see section 4.5 regarding co-administration
of Menjugate Kit with other vaccines).
Children over the age of 12 months: a single dose of 0.5 ml.
The safety and efficacy of Menjugate Kit in children aged less than 2
months have not been established. No data are
available.
Booster doses
It is recommended that a booster dose should be given after completion
of the primary immunisation series in infants.
The timing of this dose should be in accordance with available
official recommendations. Information on responses to
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_